Literature DB >> 9043664

Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.

A G Taveras1, S W Remiszewski, R J Doll, D Cesarz, E C Huang, P Kirschmeier, B N Pramanik, M E Snow, Y S Wang, J D del Rosario, B Vibulbhan, B B Bauer, J E Brown, D Carr, J Catino, C A Evans, V Girijavallabhan, L Heimark, L James, S Liberles, C Nash, L Perkins, M M Senior, A Tsarbopoulos, S E Webber.   

Abstract

The nucleotide exchange process is one of the key activation steps regulating the ras protein. This report describes the development of potent, non-nucleotide, small organic inhibitors of the ras nucleotide exchange process. These inhibitors bind to the ras protein in a previously unidentified binding pocket, without displacing bound nucleotide. This report also describes the development and use of mass spectrometry, NMR spectroscopy and molecular modeling techniques to elucidate the structure of a drug-protein complex, and aid in designing new ras inhibitor targets.

Mesh:

Substances:

Year:  1997        PMID: 9043664     DOI: 10.1016/s0968-0896(96)00202-7

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  33 in total

1.  Effect of enzyme inhibitors on protein quaternary structure determined by on-line size exclusion chromatography-microelectrospray ionization mass spectrometry.

Authors:  M L Shen; L M Benson; K L Johnson; J J Lipsky; S Naylor
Journal:  J Am Soc Mass Spectrom       Date:  2001-01       Impact factor: 3.109

2.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity.

Authors:  Till Maurer; Lindsay S Garrenton; Angela Oh; Keith Pitts; Daniel J Anderson; Nicholas J Skelton; Benjamin P Fauber; Borlan Pan; Shiva Malek; David Stokoe; Mary J C Ludlam; Krista K Bowman; Jiansheng Wu; Anthony M Giannetti; Melissa A Starovasnik; Ira Mellman; Peter K Jackson; Joachim Rudolph; Weiru Wang; Guowei Fang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 3.  KRAS as a Therapeutic Target.

Authors:  Frank McCormick
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 4.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

Review 5.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 6.  Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Authors:  Jonathan M L Ostrem; Kevan M Shokat
Journal:  Nat Rev Drug Discov       Date:  2016-07-29       Impact factor: 84.694

Review 7.  Small-molecule modulation of Ras signaling.

Authors:  Jochen Spiegel; Philipp M Cromm; Gunther Zimmermann; Tom N Grossmann; Herbert Waldmann
Journal:  Nat Chem Biol       Date:  2014-06-15       Impact factor: 15.040

8.  Inhibition of Ras-Effector Interaction by Cyclic Peptides.

Authors:  Xianghong Wu; Punit Upadhyaya; Miguel A Villalona-Calero; Roger Briesewitz; Dehua Pei
Journal:  Medchemcomm       Date:  2013-02-01       Impact factor: 3.597

Review 9.  Direct inhibition of RAS: Quest for the Holy Grail?

Authors:  Russell Spencer-Smith; John P O'Bryan
Journal:  Semin Cancer Biol       Date:  2017-12-14       Impact factor: 15.707

10.  Direct Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library.

Authors:  Punit Upadhyaya; Ziqing Qian; Nurlaila A A Habir; Dehua Pei
Journal:  Tetrahedron       Date:  2014-10-21       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.